Trexquant Investment LP Trims Holdings in Twist Bioscience Corporation $TWST

Key Points

• Trexquant Investment LP has decreased its stock position in Twist Bioscience Corporation by 11.1%, owning 149,625 shares worth approximately $5.87 million after selling 18,602 shares.
• Several hedge funds have adjusted their stakes in Twist Bioscience, with Versant Capital Management increasing its position by 547.2% during the same quarter.
• Analysts have lowered target prices for Twist Bioscience, with JPMorgan cutting its target from $40.00 to $33.00 while maintaining an "underweight" rating.

Trexquant Investment LP lowered its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 11.1% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 149,625 shares of the company's stock after selling 18,602 shares during the period. Trexquant Investment LP owned about 0.25% of Twist Bioscience worth $5,874,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Ieq Capital LLC grew its position in Twist Bioscience by 40.0% during the 1st quarter. Ieq Capital LLC now owns 86,851 shares of the company's stock worth $3,410,000 after acquiring an additional 24,817 shares during the last quarter. Rafferty Asset Management LLC boosted its position in shares of Twist Bioscience by 6.4% during the 1st quarter. Rafferty Asset Management LLC now owns 99,284 shares of the company's stock valued at $3,898,000 after purchasing an additional 5,965 shares in the last quarter. Virtus Advisers LLC bought a new stake in shares of Twist Bioscience during the 1st quarter valued at about $836,000. Hsbc Holdings PLC bought a new stake in shares of Twist Bioscience during the 1st quarter valued at about $228,000. Finally, American Century Companies Inc. boosted its position in shares of Twist Bioscience by 0.9% during the 1st quarter. American Century Companies Inc. now owns 763,406 shares of the company's stock valued at $29,971,000 after purchasing an additional 7,054 shares in the last quarter.

Insider Activity

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the completion of the sale, the chief financial officer owned 103,569 shares of the company's stock, valued at $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $60,005.28. Following the sale, the chief executive officer directly owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. This trade represents a 0.26% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,250 shares of company stock valued at $193,852. Corporate insiders own 3.01% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on TWST shares. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Evercore ISI set a $46.00 price target on Twist Bioscience in a research report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded up $0.13 during trading hours on Friday, reaching $25.76. The company had a trading volume of 1,265,895 shares, compared to its average volume of 1,537,517. The firm has a market cap of $1.55 billion, a PE ratio of -17.77 and a beta of 2.31. Twist Bioscience Corporation has a one year low of $24.28 and a one year high of $55.33. The business has a fifty day simple moving average of $31.74 and a 200 day simple moving average of $34.79. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The company had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.